Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00089713
Status:
TERMINATED
Last Update Posted:
2010-02-08
First Post:
2004-08-10
Brief Title:
Systolic Pressure Efficacy and Safety Trial of Alagebrium SPECTRA
Sponsor:
Synvista Therapeutics Inc
Organization:
Synvista Therapeutics Inc
Study Overview
Official Title:
Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients
Status:
TERMINATED
Status Verified Date:
2005-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study comprises a 3- to 6-week hydrochlorothiazide run in phase followed by a 12 week double-blind treatment phase followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase The combined total duration of patient participation is approximately 17-20 weeks Four double-blind treatment groups approximately equal in size 98 will comprise the study population placebo or various alagebrium dose groups 10 50 or 150 mgday
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None